Vol. 24 No. 2 207 43 WAS IL28B hepatitis virus HV 1.7 150 HV 7 8 HV 1975 3 HV 1 HV 20 30 Peg IFN RBV Peg IFN RBV HV 2 80 HV 2 1 50 3,4 HV HV HV Human genome project Peg IFN RBV HV 1 Peg IFN RBV sustained viral response SVR transient viral response VR non viral response NVR Masashi Mizokami 272 8516 1 7 1
208 1 IFN Factor Feature HV genotype 1 ore70 R Q, H ore91 L M ISDR 0 wild SVR SVR Peg IFN RBV SVR VR VR NVR SVR Peg IFN RBV SVR VR 5,6 48 72 VR SVR HV HV 1 70 91 NS5A interferon stimulated determination region ISDR interferon ribavirin resistance determining region IRRDR NVR 1 7 9 NVR 50 60 IRRDR 6 2000 Human genome project 2003 10 12 1 300 SNPs single nucleotide polymorphisms SNPs 1,000 SNPs SNPs SNPs SNPs HapMap 13 SNPs SNPs SNPs SNPs 14,15
Vol. 24 No. 2 209 2 IFN IL 28B Sensitive Resistant rs8105790 rs11881222 A rs8103142 rs28416813 rs4803219 rs7248668 A OR 95 I 11.1 6.6 18.6 0.1 0.04 0.12 p value 1.35 10 25 1.81 10 32 17 HV 2007 Peg IFN RBV Peg IFN RBV SNPs 6.0 array 90 SNPs enome wide association study WAS 62 SNPs SNPs Digiag2 16 VR SVR SVR & VR VR NVR NVR VR NVR 19 IL28B SNPs 17 SNPs p 3.11 10 15 odds ratio OR 30 SNPs SNPs SNPs OR 11 p 1.35 10 25 2 3 SNPs Peg IFN RBV OR 18 20 3 SVR e OR 3.1 SNPs rs12979860 SNPs HV Peg IFN RBV SNPs Suppiah Rauch SNPs OR 1.98 5.19 rs12979860 SNPs HapMap 4
210 3 WAS 4 Study e Suppiah anaka Region Northern America Northern Europe, Australia Japan Ancestry aucasian African Hispanic aucasian Japanese WAS size 871 191 75 293 142 ase control SVR vs. non SVR SVR vs. non SVR SVR vs. non SVR SVR & VR vs. NVR HV genotype 1 1 1 Significant SNPs rs12979860 p value 1.37 10 28 9.25 10 9 1.18 10 18 OR 95 I 3.1 2.1 4.7 1.98 1.57 2.52 12.1 6.5 22.4 SVR Sustained viral response, VR ransient viral response, NVR Non viral response, PE IFN Pegylated interferon alpha, RBV Ribavirin 4 2SNPs SNPs rs12979860 P value 1.21 10 28 4.37 10 26 aucasians 0.99 D African 1.00 Hispanics 1.00 Peg IFN RBV 19 NR Peg IFN RBV 13 SVR WAS WAS HV Peg IFN RBV RBV VR SVR HV IL 28B Fellay 1,286 SNPs rs6051702 20 SNPs 20 Inosine triphosphatase IPA rs1127354 rs7270101 5 21,22 Fellay rs6051702 rs7270101 rs1128354 SNPs
Vol. 24 No. 2 211 IPA SNPs rs1127354 5 SNPs Rs7270101 Population European African Hispanic ombined European African Hispanic ombined MAF 7.6 4.6 4.0 6.9 12.3 7.9 8.0 11.2 Independent p value 2.3 10 68 5.1 10 7 5.6 10 5 5.9 10 26 3.6 10 38 6.6 10 5 1.9 10 5 2.6 10 43 MAF minor allele frequency 20 6 SNPs homas Rauch SNPs rs12989760 Population European African HV mono HV & HIV combined OR 2.6 3.1 2.49 2.16 2.31 p value 1.0 10 7 1.0 10 4 1.96 10 5 8.25 10 5 6.07 10 9 HV HV 30 20,23,24 homas e rs12979860 SNPs Rauch WAS HV SNPs SNPs rs12979860 HV IL28B 6 Human immuno deficiency virus HIV HIV HV 25 4 IL28B SNPs IL28B ype IFN IFNIFN 3 26,27 IFN IFN IFN IFN IPA 28 IP RBV AP HV
212 Peg IFN RBV Peg IFN HV 29,30 SNPs WAS 1 ohen J he scientific challenge of hepatitis. Science 285 26 30, 1999 2 Rumi M, et al Randomized study of peginterferon alpha2a plus ribavirin vs peginterferon alpha2b plus ribavirin in chronic hepatitis. astroenterology 138 108 115, 2010 3 Manns MP, et al Peginterferon alfa 2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis a randomised trial. Lancet 358 958 965, 2001 4 Fried MW, et al Peginterferon alfa 2a plus ribavirin for chronic hepatitis virus infection. N Engl J Med 347 975 982, 2002 5 Buti M, et al Extending combination therapy with peginterferon alfa 2b plus ribavirin for genotype 1 chronic hepatitis late responders a report of 9 cases. Hepatology 37 1226 1227, 2003 6 Berg, et al Extended treatment duration for hepatitis virus type 1 comparing 48 versus 72 weeks of peginterferon alfa 2a plus ribavirin. astroenterology 130 1086 1097, 2006 7 Enomoto N, et al Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis virus 1b infection. N Engl J Med 334 77 81, 1996 8 El Shamy A, et al Sequence variation in hepatitis virus nonstructural protein 5A predicts clinical outcome of pegylated interferon ribavirin combination therapy. Hepatology 48 38 47, 2008 9 Akuta A, et al Association of amino acid substitution pattern in core protein of hepatitis virus genotype 1b high viral load and non virological response to interferon ribavirin combination therapy. Intervirology 48 372 380, 2005 10 Lander ES, et al Initial sequencing and analysis of the human genome. Nature 409 860 921, 2001 11 Venter J, et al he sequence of the human genome. Science 291 1304 1351, 2001 12 Finishing the euchromatic sequence of the human genome. Nature 431 931 945, 2004 13 he International HapMap Project. Nature 426 789 796, 2003 14 Kornum BR, et al ommon variants in P2RY11 are associated with narcolepsy. Nat enet 43 66 71, 2011 15 Nishida N, et al Further development of multiplex single nucleotide polymorphism typing method, the Digiag2 assay. Anal Biochem 364 78 85, 2007 16 Yasuda K, et al Variants in KNQ1 are associated with susceptibility to type 2 diabetes mellitus. Nat enet 40 1092 1097, 2008 17 anaka Y, et al enome wide association of IL28B with response to pegylated interferon alpha and ribavirin therapy for chronic hepatitis. Nat enet 41 1105 1109, 2009 18 Suppiah V, et al IL28B is associated with response to chronic hepatitis interferon alpha and ribavirin therapy. Nat enet 41 1100 1104, 2009 19 e D, et al enetic variation in IL28B predicts hepatitis treatment induced viral clearance. Nature 461 399 401, 2009 20 Fellay J, et al IPA gene variants protect against anaemia in patients treated for chronic hepatitis. Nature 464 405 408, 2010 21 Sakamoto N, et al IPA gene variant protects against anemia induced by pegylated interferon alpha and ribavirin therapy for Japanese patients with chronic hepatitis. Hepatol Res 40 1063 1071, 2010 22 Ochi H, et al IPA polymorphism affects
Vol. 24 No. 2 213 ribavirin induced anemia and outcomes of therapy a genome wide study of Japanese HV virus patients. astroenterology 139 1190 1197, 2010 23 homas DL, et al enetic variation in IL28B and spontaneous clearance of hepatitis virus. Nature 461 798 801, 2009 24 Kurbanov F, et al enetic polymorphism in IL28B is associated with spontaneous clearance of hepatitis virus genotype 4 infection in an Egyptian cohort. J Infect Dis 204 1391 1394, 2011 25 Rauch A, et al enetic variation in IL28B is associated with chronic hepatitis and treatment failure a genome wide association study. astroenterology 138 1338 1345, 2010 26 Sheppard P, et al IL 28, IL 29 and their class cytokine receptor IL 28R. Nat Immunol 4 63 68, 2003 27 Kotenko SV, et al IFN lambdas mediate antiviral protection through a distinct class cytokine receptor complex. Nat Immunol 4 69 77, 2003 28 Hitomi Y, et al Inosine triphosphate protects against ribavirin induced adenosine triphosphate loss by adenylosuccinate synthase function. astroenterology 140 1314 1321, 2011 29 hung R A watershed momnt I the treatment of hepatitis. N Engl J Med 366 273 275, 30 Dieterich D he end of the beginning for hepatitis treatment. Hepatology 55 664 665,